AG
ACRS icon

Aperio Group’s Aclaris Therapeutics ACRS Stock Holding History

Aperio Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-21,062
Closed -$35K – 2379
2020
Q2 		$35K Buy
21,062
+2,496
+13% +$3.34K ﹤0.01% 2308
2020
Q1 		$19K Sell
18,566
-279
-1% -$380 ﹤0.01% 2311
2019
Q4 		$36K Buy
18,845
+7,901
+72% +$13.1K ﹤0.01% 2307
2019
Q3 		$11K Sell
10,944
-4,082
-27% -$5.79K ﹤0.01% 2304
2019
Q2 		$33K Buy
+15,026
New +$81.9K ﹤0.01% 2610
2019
Q1 		– Sell
-24,200
Closed -$179K – 2285
2018
Q4 		$179K Buy
+24,200
New +$249K ﹤0.01% 2159

Other funds holding ACRS

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aperio Group's ACRS Position: Q3 2020 in Review

Aperio Group sold out of Aclaris Therapeutics (ACRS) in Q3 2020, closing a stake of 21,062 shares — an estimated $35K sold.

Aperio Group first reported a position in ACRS in Q4 2018 and held it in 6 quarters. The position peaked at $179K in Q4 2018. 57 funds tracked by Wall St. Rank hold ACRS as of Q3 2020.

  • Aperio Group reported no remaining Aclaris Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Aperio Group sold 21,062 Aclaris Therapeutics shares in Q3 2020, an estimated $35K.
  • Aperio Group first reported a position in Aclaris Therapeutics in Q4 2018 and held it in 6 quarters.
  • Aperio Group's Aclaris Therapeutics position peaked at $179K in Q4 2018.
  • 57 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2020.

Based on Aperio Group's 13F filing for Q3 2020, filed 6 Nov 2020.